Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Revance Therapeutics Inc RVNC

Healthcare
Revance Therapeutics, Inc. is a biotechnology company focused on developing and commercializing aesthetic and therapeutic offerings. The Company's portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers in the United States. It has also partnered with Viatris to develop a biosimilar to onabotulinumtoxinA for injection and Fosun to... see more

Recent & Breaking News (NDAQ:RVNC)

Revance Provides Corporate Update and Anticipated Milestones for 2021

Business Wire January 7, 2021

Ajinomoto Bio-Pharma Services and Revance Therapeutics Announce Manufacturing Agreement for Supply of DaxibotulinumtoxinA for Injection

PR Newswire December 22, 2020

Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire December 21, 2020

Revance Reports Positive Efficacy and Duration Results from Phase 2 Upper Facial Lines Study

Business Wire December 17, 2020

Governor Lee, Commissioner Rolfe Announce Revance Therapeutics to Relocate Global Headquarters to Nashville

Business Wire December 16, 2020

FDA Defers Approval of DaxibotulinumtoxinA for Injection in Glabellar Lines Due to COVID-19 Related Travel Restrictions Impacting Manufacturing Site Inspection

Business Wire November 25, 2020

Revance to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference

Business Wire November 24, 2020

Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire November 20, 2020

Revance to Participate in the Stifel 2020 Virtual Healthcare Conference

Business Wire November 10, 2020

Revance Reports Third Quarter 2020 Financial Results and Provides Corporate Update

Business Wire November 9, 2020

Revance Announces Results of Phase 2 Trial of DaxibotulinumtoxinA for Injection in Plantar Fasciitis

Business Wire November 9, 2020

Revance to Participate in the Credit Suisse 29th Annual Healthcare Conference

Business Wire November 3, 2020

Revance to Release Third Quarter 2020 Financial Results on Monday, November 9, 2020

Business Wire November 2, 2020

Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire October 23, 2020

Revance Reports Positive Results from ASPEN-1 Phase 3 Trial of DaxibotulinumtoxinA for Injection in Cervical Dystonia

Business Wire October 14, 2020

Revance to Present Three New Abstracts Evaluating DaxibotulinumtoxinA for Injection and Two ePosters Evaluating the RHA® Collection During the American Society for Dermatologic Surgery (ASDS) Virtual Annual Meeting

Business Wire October 6, 2020

Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire September 23, 2020

Revance to Participate in the Morgan Stanley 18th Annual Global Healthcare Conference

Business Wire September 8, 2020

Revance to Participate in the Wells Fargo Securities Healthcare Conference

Business Wire September 2, 2020

Revance Commercial Infrastructure Established and Positioned to Launch Prestige Aesthetics Portfolio with the RHA® Collection of Dermal Fillers

Business Wire August 25, 2020